Cellectis Announces First Patient to Receive CAR T-Cell Therapy Candidate
Paris-based biotechnology company Cellectis (NASDAQ: CLLS) has announced the first patient in the U.S. to receive a dose of its UCART22 allogeneic CAR T-cell therapy product candidate that was manufactured in-house at the company manufacturing facility in Raleigh.
UCART22 was developed for B-cell acute lymphoblastic leukemia (B-ALL) that has recurred or not responded to other treatment. The patient completed the initial 28-day dose-limiting toxicity period without any complications.
UCART22 is made by taking T cells from healthy donors and genetically modifying them to seek out and destroy cancer cells containing a protein called CD22. The product candidate was developed as a potential therapeutic alternative for B-ALL patients, including patients who have relapsed from or can’t receive CAR-T cells directed against the CD19 antigen.
The autologous CAR-T cell therapies currently on the market come with high costs, in part, because they rely on patient-derived T cells. This means that each therapy batch is manufactured for a single patient. Allogeneic therapies such as UCART22, however, use T cells from qualified healthy donors. This approach allows multiple patients to be treated using a single batch.
ارسال به دوستان